CAREERS AT BIOMARIN
Our focus on rare disease gives us the rare opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃DIVERSITY & INCLUSION
We value diverse perspectives from a broad spectrum of backgrounds, education, personalities, skill sets, experiences, and knowledge.
Learn More about diversity and inclusion ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies we develop.
Learn More about our patient support ⌃OUR PIPELINE
We take on the biggest challenges in rare disease.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
View Now ⌃-
January 10, 2021BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
-
January 5, 2021BioMarin to Participate in Two Upcoming Virtual Investor Conferences
-
December 21, 2020BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
-
December 1, 2020BioMarin to Participate in Two Upcoming Virtual Investor Conferences
-
November 17, 2020BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
-
November 12, 2020BioMarin to Participate in Three Upcoming Virtual Investor Conferences
-
November 9, 2020BioMarin Expands Vosoritide Clinical Program
-
November 5, 2020BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million